ClinicalTrials.gg
RecruitingNCT06400472Updated Nov 4, 2026

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

A Phase 1 interventional study of Sofe-M and bevacizumab in Ovarian Neoplasms, Endometrial Neoplasms and Uterine Cervical Neoplasms, sponsored by Eli Lilly and Company. Recruiting at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Nov 4, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
575
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Ovarian Neoplasms by Eli Lilly and Company — 6 open to participants now, 9 under way, 1 of them phase 3. Ovarian Neoplasms · Eli Lilly and Company.

Planned enrollment
5th of 26
575 · median 158
Started
2024
with 3 others
Phase 1
7 of 29
4 open now
Registered
24th of 29
by date

Among the 29 studies in Ovarian Neoplasms by Eli Lilly and Company, this one is the 5th largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 1, and was the 24th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 29 studies in Ovarian Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Ovarian Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.

03

Conditions studied

  • Ovarian Neoplasms
  • Endometrial Neoplasms
  • Uterine Cervical Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Triple Negative Breast Neoplasms
  • Pancreatic Neoplasm
  • Colorectal Neoplasms

Keywords

  • Folate receptor alpha
  • NSCLC
  • Ovarian cancer
  • Cervical cancer
  • Endometrial cancer
  • Solid tumor
  • Lung cancer
  • Breast cancer
  • Pancreatic cancer
  • Colorectal cancer
  • Anti-drug conjugate
  • Phase I
  • Chemotherapy
  • sofe-m
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have one of the following solid tumor cancers:

    • Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)
    • Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
    • Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, TNBC, and high grade endometrioid cancer

Exclusion criteria

Exclusion Criteria:

  • Individual with known or suspected uncontrolled central nervous system (CNS)
  • Individual with history of carcinomatous meningitis
  • Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  • Individual with evidence of corneal keratopathy or history of corneal transplant
  • Any serious unresolved toxicities from prior therapy
  • Significant cardiovascular disease
  • Prolongation of corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
  • History of pneumonitis/interstitial lung disease
  • Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
575 participants (estimated)

Study arms

  • Experimental
    Sofe-M (Dose-escalation, Cohort A1)

    Escalating doses of Sofe-M administered intravenously (IV)

    Drug: Sofe-M

  • Experimental
    Sofe-M (Cohort A1 Parts A and C)

    Sofe-M administered IV

    Drug: Sofe-M

  • Experimental
    Sofe-M Alone or with Itraconazole. Drug-Drug Interaction (DDI) (Cohort A1: Arm B)

    Sofe-M administered IV and itraconazole administered orally

    Drug: Sofe-M · Drug: Itraconazole

  • Experimental
    Sofe-M (Dose-optimization, Cohort A2)

    Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV

    Drug: Sofe-M

  • Experimental
    Sofe-M (Enrichment Cohort A3)

    Monotherapy administered IV

    Drug: Sofe-M

  • Experimental
    Sofe-M (Combination Cohort A4)

    Combination with bevacizumab administered IV

    Drug: Sofe-M · Drug: bevacizumab

  • Experimental
    Sofe-M (Combination Cohort A5)

    Combination with carboplatin administered IV

    Drug: Sofe-M · Drug: carboplatin

  • Experimental
    Sofe-M Combination with Pembrolizumab (Dose-optimization Cohort A6)

    Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with pembrolizumab

    Drug: Sofe-M · Drug: pembrolizumab

  • Experimental
    Sofe-M Combination with carboplatin and optional bevacizumab (Dose-optimization Cohort A7)

    Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with or without bevacizumab

    Drug: Sofe-M · Drug: bevacizumab · Drug: carboplatin

  • Experimental
    Sofe-M (Dose-expansion, Cohort B2-B4)

    Sofe-M administered IV

    Drug: Sofe-M

  • Experimental
    Sofe-M (Dose-expansion, Cohort B1)

    Sofe-M administered IV

    Drug: Sofe-M

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1a: To determine the recommended phase 2 dose (RP2D) of Sofe-M (LY4170156)

    Number of participants with dose-limiting toxicities (DLTs)

    Time frame: 1 Cycle (21 or 28 days)

  2. Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with bevacizumab

    Number of participants with DLTs

    Time frame: 1 Cycle (21 or 28 days)

  3. Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with carboplatin

    Number of participants with DLTs

    Time frame: 1 Cycle (21 or 28 days)

  4. Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with pembrolizumab

    Number of participants with DLTs

    Time frame: 1 Cycle (21 or 28 days)

  5. Phase 1b: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: Overall response rate (ORR)

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Up to Approximately 60 Months or 5 Years

  6. Phase 2: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: ORR

    ORR per RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years

  7. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Up to Approximately 60 Months or 5 Years

Secondary outcomes

  1. To characterize the pharmacokinetics (PK) properties of Sofe-M (LY4170156): Minimum Plasma Concentration (Cmin)

    PK: Cmin of Sofe-M (LY4170156)

    Time frame: First 4 Cycles (84 days)

  2. To characterize the PK properties of Sofe-M (LY4170156): Cmin with bevacizumab or carboplatin

    PK: Cmin of Sofe-M (LY4170156)

    Time frame: First 4 Cycles (Approximately 84 days)

  3. To characterize the PK properties of Sofe-M (LY4170156): Cmin with pembrolizumab

    PK: Cmin of Sofe-M (LY4170156)

    Time frame: First 4 Cycles (84 days)

  4. To characterize the PK properties of Sofe-M (LY4170156): Area under the concentration versus time curve (AUC)

    PK: AUC of Sofe-M (LY4170156)

    Time frame: First 4 Cycles (84 days)

  5. To characterize the patient-reported outcomes (PRO) Common Terminology Criteria for Adverse Events (CTCAE) of Sofe-M (LY4170156)

    PRO-CTCAE of Sofe-M (LY4170156)

    Time frame: Up to Approximately 60 Months or 5 Years

  6. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Overall response rate (ORR)

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Up to Approximately 60 Months or 5 Years

  7. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Overall response rate (ORR) with bevacizumab or carboplatin or pembrolizumab

    ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

    Time frame: Up to Approximately 60 Months or 5 Years

  8. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Duration of response (DOR)

    DOR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years

  9. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Duration of response (DOR) with bevacizumab or carboplatin or pembrolizumab

    DOR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years

  10. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Time to response (TTR)

    TTR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years

  11. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Time to response (TTR) with bevacizumab or carboplatin or pembrolizumab

    TTR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years

  12. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Progression free survival (PFS)

    PFS per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years

  13. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Progression free survival (PFS) with bevacizumab or carboplatin or pembrolizumab

    PFS per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years]

  14. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Disease control rate (DCR)

    DCR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years

  15. To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Disease control rate (DCR) with bevacizumab or carboplatin or pembrolizumab

    DCR per investigator assessed RECIST 1.1

    Time frame: Up to Approximately 60 Months or 5 Years

07

Study locations

24 of 25 sites recruiting
  • HonorHealth
    Scottsdale, Arizona 85258, United States
    Recruiting
    • · Contact480-323-1350
    • Muhammad Khawaja · Principal investigator
  • University of California, San Diego (UCSD) - Moores Cancer Center
    La Jolla, California 92037, United States
    Recruiting
    • · Contact858-657-7000
    • Ramez Eskander · Principal investigator
  • Emory University
    Atlanta, Georgia 30308, United States
    Recruiting
    • Beryl Manning-Geist · Principal investigator
  • South Texas Accelerated Research Therapeutics (START) Midwest
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • · Contact616-389-1652
    • Nehal Lakhani · Principal investigator
  • NYU Langone Health - Long Island
    Mineola, New York 11501, United States
    Recruiting
    • Bhavana Pothuri · Principal investigator
  • New York University (NYU) Clinical Cancer Center
    New York, New York 10016, United States
    Recruiting
    • · Contact212-731-5100
    • Bhavana Pothuri · Principal investigator
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Chrisann Kyi · Principal investigator
  • The Ohio State University (OSU) Wexner Medical Center
    Columbus, Ohio 43210, United States
    Recruiting
    • David O'Malley · Principal investigator
  • The University of Texas - MD Anderson Cancer Center
    Houston, Texas 77030-4000, United States
    Recruiting
    • Shannon Westin · Principal investigator
  • START Mountain Region
    West Valley City, Utah 84119, United States
    Recruiting
    • William McKean · Principal investigator
  • Inova Schar Cancer Institute
    Falls Church, Virginia 22042, United States
    Not yet recruiting
    • Leslie Randall · Principal investigator
  • Cancer Research SA
    Adelaide, 5000, Australia
    Recruiting
    • Meena Okera · Principal investigator
  • Icon Cancer Centre South Brisbane
    QLD, 4101, Australia
    Recruiting
    • Jermaine Coward · Principal investigator
  • Centre Leon Berard
    Lyon, 69373, France
    Recruiting
    • · Contact+33478782644
    • Isabelle Ray-Coquard · Principal investigator
  • Institut de Cancerologie de l'Ouest - site St-Herblain
    Saint-Herblain, 44805, France
    Recruiting
    • · Contact+33 02 40 67 99 00
    • Mario Campone · Principal investigator
  • Oncopole Claudius Regaud
    Toulouse, 31059, France
    Recruiting
    • Carlos Gomez-Roca · Principal investigator
  • Humanitas San Pio X
    Milan, 20159, Italy
    Recruiting
    • Domenica Lorusso · Principal investigator
  • Istituto Europeo di Oncologia
    Milan, 20141, Italy
    Recruiting
    • · Contact+39 02 5748 9599
    • Giuseppe Curigliano · Principal investigator
  • Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
    Recruiting
    • · Contact81120023812
    • Haruyasu Murakami · Principal investigator
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
    Recruiting
    • · Contact81120023812
    • Takafumi Koyama · Principal investigator
  • Cancer Institute Hospital of JFCR
    Tokyo, 135-8550, Japan
    Recruiting
    • · Contact81120023812
    • Shigehisa Kitano · Principal investigator
  • National Cancer Center
    Goyang-si Gyeonggi-do, 10408, South Korea
    Recruiting
    • · Contact82-1588-8110
    • Myong Cheol Lim · Principal investigator
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
    • · Contact+34 932543450
    • Roberta Mazzeo · Principal investigator
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • · Contact+34 913908922
    • Ainhoa Madariaga Urrutia · Principal investigator
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
    Recruiting
    • · Contact+34 961973527
    • Jose Alejandro Perez Fidalgo · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2029, 61 months after the start.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 61 months is above that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 6, 2024
StartActual
May 20, 2024
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Emory University is now Recruiting
Show site
  • Inova Schar Cancer Institute · Falls Church, United States
across 2 updates, Oct 7, 2026 – Nov 4, 2026
Site contacts
Changed at 24 sites. See the sites
Show 24 sites
  • HonorHealth · Scottsdale, United StatesContact added •••1350Contact added (no phone or email listed)
  • University of California, San Diego (UCSD) - Moores Cancer Center · La Jolla, United StatesContact added •••7000Contact added (no phone or email listed)
  • Emory University · Atlanta, United StatesContact added (no phone or email listed)
  • South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, United StatesContact added •••1652Contact added (no phone or email listed)
  • NYU Langone Health - Long Island · Mineola, United StatesContact added (no phone or email listed)
  • New York University (NYU) Clinical Cancer Center · New York, United StatesContact added •••5100Contact added (no phone or email listed)
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, United StatesContact added (no phone or email listed)
  • The Ohio State University (OSU) Wexner Medical Center · Columbus, United StatesContact added (no phone or email listed)
  • The University of Texas - MD Anderson Cancer Center · Houston, United StatesContact added (no phone or email listed)
  • START Mountain Region · West Valley City, United StatesContact added (no phone or email listed)
  • Cancer Research SA · Adelaide, AustraliaContact added (no phone or email listed)
  • Icon Cancer Centre South Brisbane · QLD, AustraliaContact added (no phone or email listed)
  • Centre Leon Berard · Lyon, FranceContact added •••2644Contact added (no phone or email listed)
  • Institut de Cancerologie de l'Ouest - site St-Herblain · Saint-Herblain, FranceContact added •••9900Contact added (no phone or email listed)
  • Oncopole Claudius Regaud · Toulouse, FranceContact added (no phone or email listed)
  • Humanitas San Pio X · Milan, ItalyContact added (no phone or email listed)
  • Istituto Europeo di Oncologia · Milan, ItalyContact added •••9599Contact added (no phone or email listed)
  • Shizuoka Cancer Center · Shizuoka, JapanContact added •••3812Contact added (no phone or email listed)
  • National Cancer Center Hospital · Tokyo, JapanContact added •••3812Contact added (no phone or email listed)
  • Cancer Institute Hospital of JFCR · Tokyo, JapanContact added •••3812Contact added (no phone or email listed)
  • National Cancer Center · Goyang-si Gyeonggi-do, South KoreaContact added •••8110Contact added (no phone or email listed)
  • Hospital Universitario Vall d'Hebron · Barcelona, SpainContact added •••3450Contact added (no phone or email listed)
  • Hospital Universitario 12 de Octubre · Madrid, SpainContact added •••8922Contact added (no phone or email listed)
  • Hospital Clinico Universitario de Valencia · Valencia, SpainContact added •••3527Contact added (no phone or email listed)
Oct 7, 2026
Show all 2 updates
  1. Nov 4, 2026
    Emory University is now Recruiting
    + 1 other change: verification date
  2. Oct 7, 2026
    1 site added
    Show site
    • Inova Schar Cancer Institute · Falls Church, United States
    Site contacts Changed at 24 sites. See the sites
    Show 24 sites
    • HonorHealth · Scottsdale, United StatesContact added •••1350Contact added (no phone or email listed)
    • University of California, San Diego (UCSD) - Moores Cancer Center · La Jolla, United StatesContact added •••7000Contact added (no phone or email listed)
    • Emory University · Atlanta, United StatesContact added (no phone or email listed)
    • South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, United StatesContact added •••1652Contact added (no phone or email listed)
    • NYU Langone Health - Long Island · Mineola, United StatesContact added (no phone or email listed)
    • New York University (NYU) Clinical Cancer Center · New York, United StatesContact added •••5100Contact added (no phone or email listed)
    • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, United StatesContact added (no phone or email listed)
    • The Ohio State University (OSU) Wexner Medical Center · Columbus, United StatesContact added (no phone or email listed)
    • The University of Texas - MD Anderson Cancer Center · Houston, United StatesContact added (no phone or email listed)
    • START Mountain Region · West Valley City, United StatesContact added (no phone or email listed)
    • Cancer Research SA · Adelaide, AustraliaContact added (no phone or email listed)
    • Icon Cancer Centre South Brisbane · QLD, AustraliaContact added (no phone or email listed)
    • Centre Leon Berard · Lyon, FranceContact added •••2644Contact added (no phone or email listed)
    • Institut de Cancerologie de l'Ouest - site St-Herblain · Saint-Herblain, FranceContact added •••9900Contact added (no phone or email listed)
    • Oncopole Claudius Regaud · Toulouse, FranceContact added (no phone or email listed)
    • Humanitas San Pio X · Milan, ItalyContact added (no phone or email listed)
    • Istituto Europeo di Oncologia · Milan, ItalyContact added •••9599Contact added (no phone or email listed)
    • Shizuoka Cancer Center · Shizuoka, JapanContact added •••3812Contact added (no phone or email listed)
    • National Cancer Center Hospital · Tokyo, JapanContact added •••3812Contact added (no phone or email listed)
    • Cancer Institute Hospital of JFCR · Tokyo, JapanContact added •••3812Contact added (no phone or email listed)
    • National Cancer Center · Goyang-si Gyeonggi-do, South KoreaContact added •••8110Contact added (no phone or email listed)
    • Hospital Universitario Vall d'Hebron · Barcelona, SpainContact added •••3450Contact added (no phone or email listed)
    • Hospital Universitario 12 de Octubre · Madrid, SpainContact added •••8922Contact added (no phone or email listed)
    • Hospital Clinico Universitario de Valencia · Valencia, SpainContact added •••3527Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06400472
Responsible party
Sponsor
First posted
May 6, 2024
Start date
May 20, 2024
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion